Netherlands Dermatology Drugs Market Analysis Report [2022-30]

Netherlands Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Netherlands Dermatology drugs market will reach a value of $xx Mn from $44.2 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Q-Pharma, Ipsen BV, and Galderma Benelux. The market is driven by government regulations, awareness about dermatological health, and reimbursement policies. The dermatology drug market in the Netherlands is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10NLPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Netherlands AUTHOR: Dr. Vishwa Modhia

Buy Now

Netherlands Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Netherlands' Dermatology drugs market will reach a value of $xx Mn from $44.2 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Different skin conditions are frequently reported in the Netherlands. Approximately 1-3% of the population is thought to be affected by psoriasis. In the Netherlands, it is estimated that 10–20% of children and 1-3% of adults suffer from atopic dermatitis (eczema).

Due in large part to the Netherlands' high levels of sun exposure, skin cancer is becoming a growing concern. Approximately 1–10% of Dutch people are thought to have rosacea. One of Europe's highest per capita rates for healthcare spending is in the Netherlands. According to the Organization for Economic Co-operation and Development (OECD), the Netherlands' total health expenditures made up about 11.5% of its GDP in 2019.

netherlands dermatology drugs market analysis

Market Dynamics

Market Growth Drivers

The Netherlands has seen e-commerce growth rates of over 10% per year for the previous five years, and in 2020, domestic presence in a significant portion of the region will cause this growth to accelerate.

Market Restraints

A new dermatology drug's introduction to the market in the Netherlands can be a difficult and drawn-out process that calls for extensive clinical testing and regulatory approval from the Medicines Evaluation Board (MEB). The Dutch healthcare system is highly regulated. The Dutch Healthcare Insurance Board (CVZ) has strict guidelines for dermatology drug reimbursement, and some treatments might not be eligible for reimbursement, restricting patient access to these medications.

Competitive Landscape

Key Players

Q-Pharma (NLD)
Ipsen BV (NLD)
Galderma Benelux (NLD)
Leo Pharma (NLD)
GlaxoSmithKline
Pfizer
Sanofi
Johnson & Johnson

Healthcare Regulations and Reimbursement Policies

The Netherlands' Medicines Evaluation Board (MEB), which is in charge of evaluating and approving prescription medications for use in the country, serves as the primary regulatory body for dermatology medications. The MEB functions under the direction of the Dutch Ministry of Health, Welfare, and Sport as a division of the Netherlands National Institute for Public Health and the Environment (RIVM). The MEB collaborates closely with other regulatory organizations, such as the European Medicines Agency (EMA) and the World Health Organization (WHO), to guarantee that Dutch patients have access to the newest and most potent treatments. It also offers advice to medical professionals and patients on how to use prescription medications appropriately.

The Dutch Healthcare Insurance Board (CVZ), which is in charge of deciding which prescription medications qualify for reimbursement under the Dutch basic healthcare insurance package, oversees dermatology drug reimbursement in the Netherlands. A dermatology drug must fulfill certain requirements in order to be eligible for reimbursement, including being deemed medically necessary for the treatment of a particular condition, having a favorable benefit-risk ratio in comparison to other treatments, and offering value for the money. When deciding whether to reimburse a drug, the CVZ takes into account elements like the medication's efficacy, safety, and cost-effectiveness.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.